| Friday 7.9. • 8.00–9.00 • Industry-sponsored satellite symposium | ||
|---|---|---|
| Novartis Satellite symposium | ||
| 8.00–8.05 | Opening words | Ass prof Dan Nordström Helsinki University Hospital, Department of Rheumatology |
| 8.05–8.25 | The burden of disease and importance of treating early in SpA | Lars Erik Kristensen MD PhD DMSci, CSO at the Parker Institute, Copenhagen University, Associate Professor Lund University |
| 8.25–9.00 | Structural damage in axial Spondyloarthritis | Professor Desiree van der Heijde; Leiden University Medical center, Rheumatology |
| Friday 7.9. • 17.15–18.15 • Industry-sponsored satellite symposium | ||
|---|---|---|
| Roche Satellite Symposium | ||
| Giant Cell Arteritis – A New Era in Treatment | ||
| 17.15–17.20 | Introduction | Chairman: Tom Pettersson, Professor, Clinic of General Internal Medicine and Rheumatology, Helsinki University Hospital, Department of Clinical Medicine, Helsinki University |
| 17.20–17.45 | Risk Factors and Pathogenesis of GCA | Carl Turesson, Professor, Senior Consultant, Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Department of Rheumatology, Skåne University Hospital |
| 17.45–18.10 | Tocilizumab in the Treatment of GCA | Bhaskar Dasgupta, Professor, Clinical Director Research and Audit, Honorary Professor, Essex University, Visiting Professor, Anglia Ruskin University, Honorary Professor at Queen Mary's University Hospital, London |
| 18.10–18.15 | Discussion | |
| 18.15 | End of Symposium | |
| Friday 7.9. • 17.15–18.15 • Industry-sponsored satellite symposium | ||
|---|---|---|
| Lilly RA symposium | ||
| Pain and fatigue in RA - need for improvement? | ||
| 17.15 | Introduction | Tore Kvien, Prof. Diakonhjemmet Hospital, Oslo |
| Pain and fatigue – what does the clinical research show?t | Jon Lampa, ass. Prof, Karolinska Sjukhuset, Stockholm | |
| JAK inhibitors as new treatment options – efficacy on patient reported outcomes | Tuomas Rannio, Head of Rheumatology Dept., Central Finland Central Hospital, Jyväskylä | |
| Q&A (panel discussion) | ||
| Saturday 8.9. • 8.00–9.00 • Industry-sponsored satellite symposium | ||
|---|---|---|
| Lilly PsA symposium | ||
| Management of PsA anno 2018 | ||
| 8.00 | Introduction - is the management of PsA optimal? | Lars-Erik Kristensen, MD, PhD, Prof. Parker Institute, Frederiksberg Laura Coates MD, PhD, MBChB, MRCP University of Oxford (video) |
| PsA management in the real world: Clinical Experience from a rheumatologist & dermatologist perspective | Laura Pirilä MD, PhD, Head of Rheumatology, Turku University Hospital Tarja Mälkönen MD, PhD, Head of Dermatology, University of Helsinki |
|
| New treatment option available – overview of benefits & safety | Lars-Erik Kristensen, MD, PhD, Prof. Parker Institute, Frederiksberg | |
| Discussion | ||
| Saturday 8.9. • 8.00–9.00 • Industry-sponsored satellite symposium | ||
|---|---|---|
| Pfizer satellite symposium | ||
| Tofacitinib: new treatment option in psoriatic arthritis | ||
| 7.30–8.00 | Breakfast | |
| 8.00–8.10 | Introduction | MD, Prof. Marjatta Leirisalo-Repo |
| 8.10–8.30 | Unmet Needs in Psoriatic Arthritis | MD Joonas Rautavaara |
| 8.30–8.50 | Tofacitinib in Psoriatic Arthritis | MD, Prof. Tore Kvien |
| 8.50–9.00 | Discussion & Questions | |
| 9.00 | End of symposium | |